Credit Agricole S A Sells 30,497 Shares of Zimmer Biomet Holdings, Inc. $ZBH

Key Points

• Credit Agricole S A reduced its holdings in Zimmer Biomet Holdings, Inc. by 41.8%, resulting in ownership of 42,391 shares, valued at approximately $4.8 million.
• Zimmer Biomet's earnings report showed an EPS of $2.07, which exceeded the consensus estimate of $1.98, with a quarterly revenue of $2.08 billion.
• Analysts have mixed ratings for Zimmer Biomet, with nine recommending a buy, nine a hold, and two a sell, while the current consensus price target is $111.44.

Credit Agricole S A cut its stake in Zimmer Biomet Holdings, Inc. (NYSE:ZBH - Free Report) by 41.8% during the 1st quarter, according to its most recent Form 13F filing with the SEC. The fund owned 42,391 shares of the medical equipment provider's stock after selling 30,497 shares during the period. Credit Agricole S A's holdings in Zimmer Biomet were worth $4,798,000 as of its most recent SEC filing.

Several other large investors also recently bought and sold shares of the company. Wellington Management Group LLP boosted its stake in Zimmer Biomet by 230.6% during the 1st quarter. Wellington Management Group LLP now owns 36,865 shares of the medical equipment provider's stock valued at $4,172,000 after acquiring an additional 25,713 shares during the last quarter. Korea Investment CORP boosted its stake in Zimmer Biomet by 2.8% during the 1st quarter. Korea Investment CORP now owns 99,389 shares of the medical equipment provider's stock valued at $11,249,000 after purchasing an additional 2,700 shares during the period. Brooklyn Investment Group grew its holdings in Zimmer Biomet by 45.9% in the 1st quarter. Brooklyn Investment Group now owns 461 shares of the medical equipment provider's stock worth $52,000 after buying an additional 145 shares in the last quarter. Northwest & Ethical Investments L.P. increased its holdings in shares of Zimmer Biomet by 42.0% during the first quarter. Northwest & Ethical Investments L.P. now owns 26,002 shares of the medical equipment provider's stock valued at $2,943,000 after purchasing an additional 7,689 shares during the period. Finally, Raymond James Financial Inc. lifted its stake in shares of Zimmer Biomet by 195.5% in the 1st quarter. Raymond James Financial Inc. now owns 594,097 shares of the medical equipment provider's stock worth $67,240,000 after acquiring an additional 393,077 shares during the period. Institutional investors and hedge funds own 88.89% of the company's stock.

Zimmer Biomet Price Performance

Shares of ZBH stock traded down $2.38 during trading hours on Thursday, hitting $104.41. 251,949 shares of the company's stock were exchanged, compared to its average volume of 2,031,884. Zimmer Biomet Holdings, Inc. has a 52 week low of $89.22 and a 52 week high of $116.71. The stock's 50-day moving average is $96.50 and its 200-day moving average is $99.39. The stock has a market cap of $20.68 billion, a price-to-earnings ratio of 25.42, a price-to-earnings-growth ratio of 2.12 and a beta of 0.68. The company has a debt-to-equity ratio of 0.54, a current ratio of 1.87 and a quick ratio of 0.96.

Zimmer Biomet (NYSE:ZBH - Get Free Report) last issued its quarterly earnings results on Thursday, August 7th. The medical equipment provider reported $2.07 earnings per share for the quarter, beating analysts' consensus estimates of $1.98 by $0.09. Zimmer Biomet had a net margin of 10.51% and a return on equity of 12.76%. The business had revenue of $2.08 billion during the quarter, compared to analyst estimates of $2.06 billion. During the same quarter last year, the business posted $2.01 earnings per share. Zimmer Biomet's revenue for the quarter was up 7.0% compared to the same quarter last year. Zimmer Biomet has set its FY 2025 guidance at 8.100-8.300 EPS. As a group, research analysts forecast that Zimmer Biomet Holdings, Inc. will post 8.22 EPS for the current year.

Zimmer Biomet Announces Dividend

The company also recently declared a quarterly dividend, which will be paid on Friday, October 31st. Investors of record on Tuesday, September 30th will be given a $0.24 dividend. This represents a $0.96 dividend on an annualized basis and a dividend yield of 0.9%. The ex-dividend date is Tuesday, September 30th. Zimmer Biomet's dividend payout ratio (DPR) is currently 23.36%.

Insider Activity at Zimmer Biomet

In related news, insider Sang Yi sold 1,000 shares of the firm's stock in a transaction on Wednesday, June 11th. The stock was sold at an average price of $95.00, for a total transaction of $95,000.00. Following the sale, the insider owned 20,424 shares of the company's stock, valued at approximately $1,940,280. This trade represents a 4.67% decrease in their position. The sale was disclosed in a filing with the SEC, which can be accessed through this link. 1.39% of the stock is currently owned by corporate insiders.

Wall Street Analyst Weigh In

Several analysts recently commented on the stock. Royal Bank Of Canada increased their target price on shares of Zimmer Biomet from $112.00 to $115.00 and gave the company an "outperform" rating in a research note on Friday, August 8th. Robert W. Baird dropped their price objective on shares of Zimmer Biomet from $130.00 to $115.00 and set an "outperform" rating on the stock in a research note on Tuesday, May 6th. JPMorgan Chase & Co. lowered their price target on Zimmer Biomet from $128.00 to $105.00 and set an "overweight" rating for the company in a research note on Tuesday, May 6th. JMP Securities reduced their target price on Zimmer Biomet from $140.00 to $125.00 and set a "market outperform" rating for the company in a report on Wednesday, May 7th. Finally, UBS Group raised their price target on Zimmer Biomet from $91.00 to $96.00 and gave the company a "sell" rating in a research report on Friday, August 8th. Nine equities research analysts have rated the stock with a Buy rating, nine have given a Hold rating and two have given a Sell rating to the company's stock. According to data from MarketBeat, the stock has a consensus rating of "Hold" and an average price target of $111.44.

Zimmer Biomet Profile

Zimmer Biomet Holdings, Inc, together with its subsidiaries, operates as a medical technology company worldwide. The company designs, manufactures, and markets orthopedic reconstructive products, such as knee and hip products; S.E.T. products, including sports medicine, biologics, foot and ankle, extremities, and trauma products; craniomaxillofacial and thoracic products comprising face and skull reconstruction products, as well as products that fixate and stabilize the bones of the chest to facilitate healing or reconstruction after open heart surgery, trauma, or for deformities of the chest.